Shalini Andersson, PhDSenior Director, Drug Metabolism & Pharmacokinetics at AstraZeneca
Shalini is currently the Senior Director and Head of New Therapeutic Modalities, Cardiovascular, Renal and Metabolic Innovative Medicines unit (CVRM IMED) in AstraZeneca.
Shalini has broad experience in Pharmaceutical research as well as strategic and management roles. Shalini drives several collaborations with external partners including an open innovation collaboration with Ionis Pharmaceuticals and the delivery of modified RNA to man with Moderna Therapeutics. Shalini is also involved in several academic collaborations across the globe.
Prior to this role, Shalini held several leadership roles within CVRM Drug Metabolism & Pharmacokinetics and in Medicinal Chemistry.
Shalini received her PhD in 1989 at the University of Linköping, Sweden and has held various research and teaching positions at the University of Linköping prior to moving to industry. She is the author or co-author of over 35 peer reviewed articles, 2 book chapters and 4 patents.